17 matches for your search in the start-up spotlight
rss
05-May-2025
A record number of over 320 innovators from the international life-science community gathered in Munich for the 17th BioVaria, Europe’s premier event for showcasing commercially attractive inventions and start-ups. A highlight was the BioVaria Startup Pitch & Partner Program, where 10 handpicked ...
Innovate Nordics targets Nordic growth companies aiming to establish a presence in the U.S. market
30-Apr-2025
Neogap Therapeutics, a Swedish biotechnology start-up developing personalised immunotherapy for cancer treatment, announced that it has been selected for the Innovate Nordics 2025 Acceleration Program, organised by the Swedish-American Chamber of Commerce in New York (SACCNY) in partnership with ...
Pathios Therapeutics raises $25M in first close of Series B financing to advance first-in-class immunotherapy approach into clinic
23-Apr-2024
Pathios Therapeutics Limited, a biotech company focused on the development of first-in-class therapies for cancer, announced that the company has raised USD $25 million in the first close of a Series B financing. The financing consists of a new strategic investment from Bristol Myers Squibb, as ...
New European and US investors: Nouscom Raises €67.5 million in Oversubscribed Series C Financing Round
15-Nov-2023
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned ...
06-Sep-2023
iOmx Therapeutics AG (iOmx), a clinical stage biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, announced the appointment of Dr. Nils Peter Debus as Chief Business Officer (CBO) to drive the company’s new stage of growth. Dr. Debus is an ...
A total of sixteen teams presented their innovative ideas to almost 50 investors at the Munich start-up center.
18-Jul-2023
On July 13, 2023, the Munich Innovation and Start-up Center for Biotechnology (IZB) organized the 8th Life Science Pitch Day in cooperation with High-Tech Gründerfonds (HTGF), Leaps by Bayer, and Boehringer Ingelheim, which brought together sixteen biotech start-ups and project teams and almost ...
Focus on accelerated development of differentiated antibody-drug conjugates therapeutics for solid tumors
04-Apr-2023
BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. (DualityBio), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate (“ADC”) therapeutics to treat patients with cancer and autoimmune diseases, announced that the companies have ...
SPRIND to finance spin-off Plectonic
30-Nov-2022
The Federal Agency for Disruptive Innovation SPRIND will provide funding for the work of Plectonic Biotech in the coming years. The TUM spin-off has developed a nanoswitch that binds immune cells to tumor cells. The goal is to facilitate the development of immunotherapies that target tumors ...
Start-up develops a "new anti-cancer immunotherapeutic drug with the potential to transform the immuno-oncology landscape"
24-Nov-2022
CatalYm announced the close of a EUR50 million (USD49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, ...
24-May-2022
KaliVir Immunotherapeutics, Inc. announced a collaboration and global exclusive licensing agreement with Roche for the discovery, development and commercialization of novel oncolytic vaccinia viruses derived from KaliVir's oncolytic immunotherapy VETTM platform. KaliVir will work with Roche to ...
